Page last updated: 2024-09-21

kynuramine

Description

Kynuramine: An aromatic ketone containing the aniline structure (ANILINE COMPOUNDS). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

kynuramine : A member of the class of kynurenamines that is aniline substituted at position 2 by a 3-aminopropanoyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9692
CHEMBL ID23319
CHEBI ID73472
SCHEMBL ID2801613
MeSH IDM0012090

Synonyms (22)

Synonym
NCGC00163347-01
diaminopropiophenone
kynuramine
CHEMBL23319
chebi:73472 ,
3-amino-1-(2-aminophenyl)propan-1-one
363-36-0
1-propanone, 3-amino-1-(2-aminophenyl)-
2wr44bv65e ,
unii-2wr44bv65e
AKOS006306798
QLPVTIQQFGWSQQ-UHFFFAOYSA-N
bdbm10990
3-(2-aminophenyl)-3-oxopropanamine
SCHEMBL2801613
DTXSID70189836
3-amino-1-(2-aminophenyl)-1-propanone
Q27140555
1-(2-aminophenyl)-3-azanyl-propan-1-one
methyl3-(diethylamino)propanoate
SB76139
EN300-207294

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
kynurenamines
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency19.95260.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency2.81840.011212.4002100.0000AID1030
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
monoamine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BBos taurus (cattle)
mitochondrial outer membraneAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID102567Turnover number against MAO A (umol of substrate/min per umol of enzyme).1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Molecular size and flexibility as determinants of selectivity in the oxidation of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs by monoamine oxidase A and B.
AID488102Ratio of Vmax to Km for baboon liver mitochondrial MAO-B assessed per mg of protein after 6 mins2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.
AID102737Turnover number (TN) for human mono-amine oxidase MAO-A1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Novel 4-(aryloxy)tetrahydropyridine analogs of MPTP as monoamine oxidase A and B substrates.
AID102576Turnover number against MAO B (umol of substrate/min per umol of enzyme).1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Molecular size and flexibility as determinants of selectivity in the oxidation of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs by monoamine oxidase A and B.
AID231695Ratio between TN and Km against MAO A1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Molecular size and flexibility as determinants of selectivity in the oxidation of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs by monoamine oxidase A and B.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID102736Oxidation by human mono-amine oxidase MAO-A1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Novel 4-(aryloxy)tetrahydropyridine analogs of MPTP as monoamine oxidase A and B substrates.
AID488083Activity at baboon liver mitochondrial MAO-B assessed as H2O2 production at 500 uM after 6 to 15 mins pretreated with (R)-deprenyl2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.
AID488101Activity at baboon liver mitochondrial MAO-B assessed as initial rate of H2O2 production after 6 mins2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.
AID102566Michaelis-Menten constant against MAO A.1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Molecular size and flexibility as determinants of selectivity in the oxidation of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs by monoamine oxidase A and B.
AID488100Activity at baboon liver mitochondrial MAO-B assessed as initial rate of H2O2 production after 6 mins assessed per mg of mitochondrial protein2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.
AID229921Ratio of turnover to Km for human MAO-A1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Novel 4-(aryloxy)tetrahydropyridine analogs of MPTP as monoamine oxidase A and B substrates.
AID29986Ratio between TN and Km against MAO B1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Molecular size and flexibility as determinants of selectivity in the oxidation of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs by monoamine oxidase A and B.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID102575Michaelis-Menten constant against MAO B.1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Molecular size and flexibility as determinants of selectivity in the oxidation of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs by monoamine oxidase A and B.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (187)

TimeframeStudies, This Drug (%)All Drugs %
pre-199066 (35.29)18.7374
1990's13 (6.95)18.2507
2000's62 (33.16)29.6817
2010's35 (18.72)24.3611
2020's11 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (4.74%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other181 (95.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Bioavailability (1)

ArticleYear
One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?
Journal of pineal research, Volume: 42, Issue: 1
2007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (4)

ArticleYear
Effect of melatonin in the antioxidant defense system in the locomotor muscles of the estuarine crab Neohelice granulata (Decapoda, Brachyura).
General and comparative endocrinology, Mar-01, Volume: 166, Issue: 1
2010
Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin.
Journal of neurochemistry, Volume: 98, Issue: 6
2006
N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Volume: 15, Issue: 12
2001
Analysis of the effect of 5-hydroxykynurenamine,, a serotonin metabolite, on isolated cerebral arteries, aortas and atria.
The Journal of pharmacology and experimental therapeutics, Volume: 193, Issue: 2
1975
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]